Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Drug Delivery in Cancer Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Drug Delivery in Cancer Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Drug Delivery in Cancer Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Liposomes
    • 1.4.3 PEGylated Proteins & Polypeptides
    • 1.4.4 Polymer Nanoparticle
    • 1.4.5 Protein–drug Conjugates
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Drug Delivery in Cancer Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals & Clinic
    • 1.5.3 Cancer Treatment Centers
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Drug Delivery in Cancer Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Drug Delivery in Cancer Industry
      • 1.6.1.1 Drug Delivery in Cancer Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Drug Delivery in Cancer Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Drug Delivery in Cancer Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Drug Delivery in Cancer Market Perspective (2015-2026)
  • 2.2 Drug Delivery in Cancer Growth Trends by Regions
    • 2.2.1 Drug Delivery in Cancer Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Drug Delivery in Cancer Historic Market Share by Regions (2015-2020)
    • 2.2.3 Drug Delivery in Cancer Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Drug Delivery in Cancer Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Drug Delivery in Cancer Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Drug Delivery in Cancer Players by Market Size
    • 3.1.1 Global Top Drug Delivery in Cancer Players by Revenue (2015-2020)
    • 3.1.2 Global Drug Delivery in Cancer Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Drug Delivery in Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Drug Delivery in Cancer Market Concentration Ratio
    • 3.2.1 Global Drug Delivery in Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Drug Delivery in Cancer Revenue in 2019
  • 3.3 Drug Delivery in Cancer Key Players Head office and Area Served
  • 3.4 Key Players Drug Delivery in Cancer Product Solution and Service
  • 3.5 Date of Enter into Drug Delivery in Cancer Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Drug Delivery in Cancer Historic Market Size by Type (2015-2020)
  • 4.2 Global Drug Delivery in Cancer Forecasted Market Size by Type (2021-2026)

5 Drug Delivery in Cancer Breakdown Data by Application (2015-2026)

  • 5.1 Global Drug Delivery in Cancer Market Size by Application (2015-2020)
  • 5.2 Global Drug Delivery in Cancer Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Drug Delivery in Cancer Market Size (2015-2020)
  • 6.2 Drug Delivery in Cancer Key Players in North America (2019-2020)
  • 6.3 North America Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 6.4 North America Drug Delivery in Cancer Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Drug Delivery in Cancer Market Size (2015-2020)
  • 7.2 Drug Delivery in Cancer Key Players in Europe (2019-2020)
  • 7.3 Europe Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 7.4 Europe Drug Delivery in Cancer Market Size by Application (2015-2020)

8 China

  • 8.1 China Drug Delivery in Cancer Market Size (2015-2020)
  • 8.2 Drug Delivery in Cancer Key Players in China (2019-2020)
  • 8.3 China Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 8.4 China Drug Delivery in Cancer Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Drug Delivery in Cancer Market Size (2015-2020)
  • 9.2 Drug Delivery in Cancer Key Players in Japan (2019-2020)
  • 9.3 Japan Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 9.4 Japan Drug Delivery in Cancer Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Drug Delivery in Cancer Market Size (2015-2020)
  • 10.2 Drug Delivery in Cancer Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Drug Delivery in Cancer Market Size by Application (2015-2020)

11 India

  • 11.1 India Drug Delivery in Cancer Market Size (2015-2020)
  • 11.2 Drug Delivery in Cancer Key Players in India (2019-2020)
  • 11.3 India Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 11.4 India Drug Delivery in Cancer Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Drug Delivery in Cancer Market Size (2015-2020)
  • 12.2 Drug Delivery in Cancer Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Drug Delivery in Cancer Market Size by Type (2015-2020)
  • 12.4 Central & South America Drug Delivery in Cancer Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Amgen
    • 13.1.1 Amgen Company Details
    • 13.1.2 Amgen Business Overview and Its Total Revenue
    • 13.1.3 Amgen Drug Delivery in Cancer Introduction
    • 13.1.4 Amgen Revenue in Drug Delivery in Cancer Business (2015-2020))
    • 13.1.5 Amgen Recent Development
  • 13.2 Teva
    • 13.2.1 Teva Company Details
    • 13.2.2 Teva Business Overview and Its Total Revenue
    • 13.2.3 Teva Drug Delivery in Cancer Introduction
    • 13.2.4 Teva Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.2.5 Teva Recent Development
  • 13.3 UCB (Union Chimique Belge)
    • 13.3.1 UCB (Union Chimique Belge) Company Details
    • 13.3.2 UCB (Union Chimique Belge) Business Overview and Its Total Revenue
    • 13.3.3 UCB (Union Chimique Belge) Drug Delivery in Cancer Introduction
    • 13.3.4 UCB (Union Chimique Belge) Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.3.5 UCB (Union Chimique Belge) Recent Development
  • 13.4 Roche
    • 13.4.1 Roche Company Details
    • 13.4.2 Roche Business Overview and Its Total Revenue
    • 13.4.3 Roche Drug Delivery in Cancer Introduction
    • 13.4.4 Roche Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.4.5 Roche Recent Development
  • 13.5 Celgene
    • 13.5.1 Celgene Company Details
    • 13.5.2 Celgene Business Overview and Its Total Revenue
    • 13.5.3 Celgene Drug Delivery in Cancer Introduction
    • 13.5.4 Celgene Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.5.5 Celgene Recent Development
  • 13.6 Sanofi
    • 13.6.1 Sanofi Company Details
    • 13.6.2 Sanofi Business Overview and Its Total Revenue
    • 13.6.3 Sanofi Drug Delivery in Cancer Introduction
    • 13.6.4 Sanofi Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.6.5 Sanofi Recent Development
  • 13.7 Merck
    • 13.7.1 Merck Company Details
    • 13.7.2 Merck Business Overview and Its Total Revenue
    • 13.7.3 Merck Drug Delivery in Cancer Introduction
    • 13.7.4 Merck Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.7.5 Merck Recent Development
  • 13.8 Johnson & Johnson
    • 13.8.1 Johnson & Johnson Company Details
    • 13.8.2 Johnson & Johnson Business Overview and Its Total Revenue
    • 13.8.3 Johnson & Johnson Drug Delivery in Cancer Introduction
    • 13.8.4 Johnson & Johnson Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.8.5 Johnson & Johnson Recent Development
  • 13.9 Takeda
    • 13.9.1 Takeda Company Details
    • 13.9.2 Takeda Business Overview and Its Total Revenue
    • 13.9.3 Takeda Drug Delivery in Cancer Introduction
    • 13.9.4 Takeda Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.9.5 Takeda Recent Development
  • 13.10 Gilead Sciences
    • 13.10.1 Gilead Sciences Company Details
    • 13.10.2 Gilead Sciences Business Overview and Its Total Revenue
    • 13.10.3 Gilead Sciences Drug Delivery in Cancer Introduction
    • 13.10.4 Gilead Sciences Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 13.10.5 Gilead Sciences Recent Development
  • 13.11 Pfizer
    • 10.11.1 Pfizer Company Details
    • 10.11.2 Pfizer Business Overview and Its Total Revenue
    • 10.11.3 Pfizer Drug Delivery in Cancer Introduction
    • 10.11.4 Pfizer Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.11.5 Pfizer Recent Development
  • 13.12 Dr Reddy
    • 10.12.1 Dr Reddy Company Details
    • 10.12.2 Dr Reddy Business Overview and Its Total Revenue
    • 10.12.3 Dr Reddy Drug Delivery in Cancer Introduction
    • 10.12.4 Dr Reddy Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.12.5 Dr Reddy Recent Development
  • 13.13 Samyang Biopharmaceuticals
    • 10.13.1 Samyang Biopharmaceuticals Company Details
    • 10.13.2 Samyang Biopharmaceuticals Business Overview and Its Total Revenue
    • 10.13.3 Samyang Biopharmaceuticals Drug Delivery in Cancer Introduction
    • 10.13.4 Samyang Biopharmaceuticals Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.13.5 Samyang Biopharmaceuticals Recent Development
  • 13.14 Tolmar
    • 10.14.1 Tolmar Company Details
    • 10.14.2 Tolmar Business Overview and Its Total Revenue
    • 10.14.3 Tolmar Drug Delivery in Cancer Introduction
    • 10.14.4 Tolmar Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.14.5 Tolmar Recent Development
  • 13.15 Astellas
    • 10.15.1 Astellas Company Details
    • 10.15.2 Astellas Business Overview and Its Total Revenue
    • 10.15.3 Astellas Drug Delivery in Cancer Introduction
    • 10.15.4 Astellas Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.15.5 Astellas Recent Development
  • 13.16 AMAG Pharmaceuticals
    • 10.16.1 AMAG Pharmaceuticals Company Details
    • 10.16.2 AMAG Pharmaceuticals Business Overview and Its Total Revenue
    • 10.16.3 AMAG Pharmaceuticals Drug Delivery in Cancer Introduction
    • 10.16.4 AMAG Pharmaceuticals Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.16.5 AMAG Pharmaceuticals Recent Development
  • 13.17 AstraZeneca
    • 10.17.1 AstraZeneca Company Details
    • 10.17.2 AstraZeneca Business Overview and Its Total Revenue
    • 10.17.3 AstraZeneca Drug Delivery in Cancer Introduction
    • 10.17.4 AstraZeneca Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.17.5 AstraZeneca Recent Development
  • 13.18 AbbVie
    • 10.18.1 AbbVie Company Details
    • 10.18.2 AbbVie Business Overview and Its Total Revenue
    • 10.18.3 AbbVie Drug Delivery in Cancer Introduction
    • 10.18.4 AbbVie Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.18.5 AbbVie Recent Development
  • 13.19 Novartis
    • 10.19.1 Novartis Company Details
    • 10.19.2 Novartis Business Overview and Its Total Revenue
    • 10.19.3 Novartis Drug Delivery in Cancer Introduction
    • 10.19.4 Novartis Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.19.5 Novartis Recent Development
  • 13.20 Aspen
    • 10.20.1 Aspen Company Details
    • 10.20.2 Aspen Business Overview and Its Total Revenue
    • 10.20.3 Aspen Drug Delivery in Cancer Introduction
    • 10.20.4 Aspen Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.20.5 Aspen Recent Development
  • 13.21 Shire (Baxalta)
    • 10.21.1 Shire (Baxalta) Company Details
    • 10.21.2 Shire (Baxalta) Business Overview and Its Total Revenue
    • 10.21.3 Shire (Baxalta) Drug Delivery in Cancer Introduction
    • 10.21.4 Shire (Baxalta) Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.21.5 Shire (Baxalta) Recent Development
  • 13.22 Breckenridge Pharmaceuticals
    • 10.22.1 Breckenridge Pharmaceuticals Company Details
    • 10.22.2 Breckenridge Pharmaceuticals Business Overview and Its Total Revenue
    • 10.22.3 Breckenridge Pharmaceuticals Drug Delivery in Cancer Introduction
    • 10.22.4 Breckenridge Pharmaceuticals Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.22.5 Breckenridge Pharmaceuticals Recent Development
  • 13.23 Galen Pharmaceuticals
    • 10.23.1 Galen Pharmaceuticals Company Details
    • 10.23.2 Galen Pharmaceuticals Business Overview and Its Total Revenue
    • 10.23.3 Galen Pharmaceuticals Drug Delivery in Cancer Introduction
    • 10.23.4 Galen Pharmaceuticals Revenue in Drug Delivery in Cancer Business (2015-2020)
    • 10.23.5 Galen Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Drug Delivery in Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Drug Delivery in Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Amgen
    Teva
    UCB (Union Chimique Belge)
    Roche
    Celgene
    Sanofi
    Merck
    Johnson & Johnson
    Takeda
    Gilead Sciences
    Pfizer
    Dr Reddy
    Samyang Biopharmaceuticals
    Tolmar
    Astellas
    AMAG Pharmaceuticals
    AstraZeneca
    AbbVie
    Novartis
    Aspen
    Shire (Baxalta)
    Breckenridge Pharmaceuticals
    Galen Pharmaceuticals

    Market segment by Type, the product can be split into
    Liposomes
    PEGylated Proteins & Polypeptides
    Polymer Nanoparticle
    Protein–drug Conjugates
    Others
    Market segment by Application, split into
    Hospitals & Clinic
    Cancer Treatment Centers
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Drug Delivery in Cancer status, future forecast, growth opportunity, key market and key players.
    To present the Drug Delivery in Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Drug Delivery in Cancer are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now